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Genetic background influences pig growth rate responses to porcine circovirus
type 2 (pcv2) vaccines
Abstract
A total of 454 pigs (21 d of age, 13.4 lb) were used in a 130-d field study to investigate porcine circovirus
type 2 (PCV2) vaccine effects on growth performance of boars and gilts of 4 different genetic
backgrounds: AÃ—A (Duroc-based sire and dam), BÃ—B (synthetic line sire and dam lines derived from
Duroc, Pie-train, and Large White), AÃ—B, and BÃ—A. Pigs were identified as potential test pigs at birth
and ear tagged for identification. Characteristics including litter, genetic background, gender, and birth
weight were recorded and used in allotting PCV2 vaccine treatment groups. Pigs were vaccinated
according to label dose with a 2-dose commercial PCV2 vaccine (Circumvent PCV, Intervet Inc., Millsboro,
DE) at weaning (d 0) and again 14 d later. Vaccinated and control pigs were comingled within the same
pen for the duration of the study. Pigs were individually weighed on d 0, 40, and 130 to measure growth
rate. Backfat and loin depth were measured on d 130 by using real-time ultra-sound. Blood was collected
on d 0, 40, and 130 for indirect fluorescent antibody measurement of PCV2 antibodies and polymerase
chain reaction (PCR) analysis for determination of PCV2 virus load. By d 130, vaccinates were heavier (P <
0.01) than controls. However, the magnitude of the weight difference between control and vaccinates was
almost 4 times greater in the AÃ—A pigs than in the BÃ—B pigs (P < 0.05). On the basis of growth
performance, the different genetic backgrounds responded differently to the PCV2 vaccination even
though they were comingled in the same pen. In the 2 pure-line populations, even the best performing
portion of the population appeared to benefit from vaccination, suggesting that growth performance of
most pigs is being affected by PCV2 infection. Control pigs exhibited a late increase in PCV2 antibody
levels, a consequence of natural infection. In contrast, vaccinated pigs did not exhibit a late-finisher
antibody rise. Vaccinated pigs possessed a decreased viral load (as quantified by PCR PCV2 viral DNA) at
both d 40 and 130. The data demonstrate that genetic background affects either the expression of
porcine circoviral disease or the response to the PCV2 vaccine.; Swine Day, 2008, Kansas State University,
Manhattan, KS, 2008

Keywords
Swine day, 2008; Kansas Agricultural Experiment Station contribution; no. 09-074-S; Report of progress
(Kansas State University. Agricultural Experiment Station and Cooperative Extension Service); 1001;
Circovirus; Genetics; Growth; PCV2; Swine; Vaccination

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.

Authors
M L. Potter, Lisa M. Tokach, Steven C. Henry, Joel M. DeRouchey, Michael D. Tokach, Raymond R. Rowland
R, Richard D. Oberst, Richard A. Hesse, Robert D. Goodband, Jim L. Nelssen, and Steven S. Dritz

This research report is available in Kansas Agricultural Experiment Station Research Reports:
https://newprairiepress.org/kaesrr/vol0/iss10/1168

Swine Day 2008

GENETIC BACKGROUND INFLUENCES PIG GROWTH RATE RESPONSES
TO PORCINE CIRCOVIRUS TYPE 2 (PCV2) VACCINES1
M. L. Potter2, L. M. Tokach3, S. S. Dritz2, S. C. Henry3, J. M. DeRouchey, M. D. Tokach,
R. D. Goodband, J. L. Nelssen, R.R.R. Rowland2, R. D. Oberst2, and R. A. Hesse2

By d 130, vaccinates were heavier (P <
0.01) than controls. However, the magnitude
of the weight difference between control and
vaccinates was almost 4 times greater in the
A×A pigs than in the B×B pigs (P < 0.05).
On the basis of growth performance, the different genetic backgrounds responded differently to the PCV2 vaccination even though
they were comingled in the same pen. In the 2
pure-line populations, even the best performing portion of the population appeared to benefit from vaccination, suggesting that growth
performance of most pigs is being affected by
PCV2 infection.

Summary
A total of 454 pigs (21 d of age, 13.4 lb)
were used in a 130-d field study to investigate
porcine circovirus type 2 (PCV2) vaccine effects on growth performance of boars and gilts
of 4 different genetic backgrounds: A×A (Duroc-based sire and dam), B×B (synthetic line
sire and dam lines derived from Duroc, Pietrain, and Large White), A×B, and B×A.
Pigs were identified as potential test pigs
at birth and ear tagged for identification. Characteristics including litter, genetic background, gender, and birth weight were recorded and used in allotting PCV2 vaccine
treatment groups. Pigs were vaccinated according to label dose with a 2-dose commercial PCV2 vaccine (Circumvent PCV, Intervet
Inc., Millsboro, DE) at weaning (d 0) and
again 14 d later. Vaccinated and control pigs
were comingled within the same pen for the
duration of the study. Pigs were individually
weighed on d 0, 40, and 130 to measure
growth rate. Backfat and loin depth were
measured on d 130 by using real-time ultrasound. Blood was collected on d 0, 40, and
130 for indirect fluorescent antibody measurement of PCV2 antibodies and polymerase
chain reaction (PCR) analysis for determination of PCV2 virus load.

Control pigs exhibited a late increase in
PCV2 antibody levels, a consequence of natural infection. In contrast, vaccinated pigs did
not exhibit a late-finisher antibody rise. Vaccinated pigs possessed a decreased viral load
(as quantified by PCR PCV2 viral DNA) at
both d 40 and 130. The data demonstrate that
genetic background affects either the expression of porcine circoviral disease or the response to the PCV2 vaccine.
Key words: circovirus, genetics, growth,
PCV2, swine, vaccination
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control). Birth weight was balanced across
vaccine treatment. Genetic background included pure lines of A×A (Duroc-based sire
and dam) and B×B (synthetic line for the sire
and dam primarily derived from Duroc, Pietrain, and Large White) and crossbreds A×B
and B×A.

Introduction
The primary agent of porcine circoviral
disease (PCVD) is porcine circovirus type 2
(PCV2). The approved case definition for
PCVD defines a PCVD herd as one which
demonstrates one or more of the following
clinical manifestations: wasting, respiratory or
enteric signs, high mortality, porcine dermatitis and nephropathy syndrome, or reproductive
disorders. Porcine circoviral disease is confirmed by finding microscopic lesions consistent with the disease in affected pigs as well as
the presence of viral antigen in tissues.

Vaccine treatment pigs were vaccinated
intramuscularly with a 2-dose commercial
PCV2 vaccine (Circumvent PCV, Intervet Inc,
Millsboro, DE) according to label dose at 21
and 35 d of age. Vaccinated pigs were comingled with nonvaccinated control pigs for the
duration of the trial.

Reported risk factors associated with
PCVD include litter of origin, management
factors, and gender as well as genetics. Only
limited, controlled research has been completed to define the role of these risk factors in
the development and expression of PCVD and
response to vaccination. The focus of this
study was to further elucidate the contribution
of genetic background to PCVD by comparing
the response of different genetic lines of pigs
to PCV2 vaccination in a high-health herd
with naturally circulating PCV2.

Pigs were individually weighed and bled
at birth, weaning (d 0), end of nursery (d 40),
and off test (d 130). Loin depth and backfat
measurements were collected by using realtime ultrasound on d 130.
Removals and deaths were recorded during all phases. There were 6 deaths in the nursery phase, 25 deaths in the finisher phase,
and 6 other records removed because of data
entry errors or unrelated physical defects. Data
analysis was performed on the 417 pigs that
had complete growth records.

Procedures

Comparisons between vaccinates and nonvaccinated controls, genetic background, and
gender were made in a 2 × 4 × 2 factorial
treatment design. Litter of origin was managed
as a random effect. Statistical analysis was
performed by using the Proc GLIMMIX procedure of SAS to obtain least square means
and standard errors for the response criteria.

A 1,700-sow multiplier farm in Kansas
was used for this field study. This single-site
farm maintains a high-health status; it is porcine reproductive and respiratory syndrome
virus negative and without evidence of Mycoplasma hyopneumoniae infection since its
stocking in 2000. Despite the high-health status, the presence of PCV2b virus had been documented in this herd. However, the primary
concern was an increase in morbidity characterized by ill-thrift and slow growing pigs as
mortality was within the expected historic
range on this farm.

Results
Despite active PCV2 infection, there was
no discernable pattern of mortality among the
genetic backgrounds, and overall mortality
was similar between vaccinates (6.8%) and
controls (7.0%). There were no 3-way gender
× genetic background × vaccine interactions
found for the response criteria in this study
with the exception of backfat depth after

For this 130-d study, a total of 454 pigs
from 4 genetic backgrounds were ranked by
birth weight within litter and gender (boar or
gilt) and randomly assigned to PCV2 vaccine
treatment group (vaccinated or nonvaccinated
6

Prior to adjusting backfat and loin depths
to a common off-test weight, it appeared there
were significant differences in loin depth and
numerical differences in backfat measurement
between vaccine treatment groups. After adjustment, there was a genetic background effect (P < 0.01) for loin depth as well as a 3way gender × genetic background × vaccine
interaction (P = 0.02) for backfat measurement. Despite the 3-way interaction for backfat depth, there was no significant effect of
vaccination on backfat (P = 0.62) or loin
depth (P = 0.29) after adjustment to a common off-test weight.

weight adjustment. The significant interaction
(P = 0.02) was the result of control A×B crossbred boars having a higher weight-adjusted
backfat depth than vaccinated A×B crossbred
boars (11.9 ± 0.4 mm for controls vs. 10.9 ±
0.4 mm for vaccinates). Within all other gender by genetic background combinations,
backfat depth was similar between controls
and vaccinates.
Weaning age and weight and off-test age
were not different for the vaccine × genetic
background least squares means (Table 1). A
vaccine × genetic background interaction was
noted for nursery ADG, finisher ADG, and
overall wean-to-finish ADG (P = 0.05, P =
0.05, and P = 0.04, respectively). In the nursery phase, this interaction was due to the A×B
vaccinates having lower (P = 0.04) ADG than
A×B controls. In contrast, B×A and B×B vaccinates had numerically higher ADG than controls. For the A×A pigs, controls and vaccinates had similar ADG. Therefore, in the
nursery period of this study, genetic background did affect how vaccinates performed
compared with controls; controls demonstrated higher nursery ADG in a single genetic
background, whereas in the other lines, there
was little to no performance difference between vaccinates and controls. Although the
interaction was statistically significant, we are
unsure of the biologic significance. In the finisher phase of production, ADG was lower (P
< 0.01) for the A×A controls than for the control pigs of A×B, B×A, and B×B. In contrast,
A×A vaccinates had similar ADG to all
groups except A×B (P = 0.04). Thus, the
magnitude of the difference between control
and vaccinate groups was greater for the A×A
pigs than for B×B and crossbred pigs. Weanto-finish ADG followed a pattern similar to
that of finisher ADG.

Indirect fluorescent antibody analysis
demonstrated antibody responses to both vaccine and natural PCV2 exposure (Figure 1). In
response to vaccination, vaccinates had increased (P < 0.01) antibody production by d
40 compared with controls, but as a result of
natural PCV2 exposure, controls demonstrated
a rise (P < 0.01) in antibody levels compared
with vaccinates by d 130. PCV2 DNA template copies per reaction provided an estimate
of viral load (Figure 2). PCV2 vaccination reduced mean viral load in vaccinates compared
with controls at both d 40 (P < 0.01) and 130
(P < 0.01)
Discussion
The results from this study demonstrate
that genetic background affects response to
PCV2 vaccination or PCVD expression as
measured by growth rate. The findings in this
study are unique because this herd did not fit
the accepted case definition for PCVD; yet,
this study clearly demonstrates that PCV2
vaccination improved the growth performance
of vaccinated pigs compared with controls.
The difference in magnitude of the finisher
ADG and wean-to-finish ADG was 3 and 5
times greater, respectively, in A×A pigs than
in B×B pigs. In addition, within each crossbred genetic background, vaccinated pigs consistently had numerically increased ADG
compared with controls. Vaccinated pigs were

At d 130, A×A control pigs weighed less
(P < 0.01) than controls from the other 3 genetic backgrounds, whereas A×A vaccinates
weighed less (P = 0.04) than B×A vaccinates.
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the higher PCV2 antibody titers in the vaccinates compared with controls. A rise in antibody titer in the control pigs from d 40 to 130
indicated active PCV2 infection due to field
virus exposure during the trial period. In contrast, vaccinates had a decrease in PCV2 antibody titer from d 40 to 130, which suggests
that vaccinates have increased resistance to
infection. The results of this study support
previous research findings that PCV2 vaccination effectively decreases viral load, even under comingled conditions. Controls had a larger quantity of viral templates per reaction
compared with vaccinates at d 40. By d 130,
the difference between the treatment groups
remained; however, mean template copies per
reaction were reduced to 3.8 for controls compared with 1.3 for vaccinates. The biologic
significance of these viral load quantities remains to be determined; however, the potential for the PCV2 vaccine to aid in the reduction of viremia and viral shedding is apparent.

19.7, 6.2, 10.2, and 5.0 lb heavier compared
with nonvaccinated controls for A×A, A×B,
B×A, and B×B genetic backgrounds, respectively. Similar to other studies we have conducted, PCV2-vaccinated pigs demonstrated
increased growth rate during the finisher
phase. However, the magnitude of the weight
difference was almost 4 times greater in the
A×A pigs than in the B×B pigs. Although the
B×B pigs grew faster than the A×A pigs, they
had a similar overall pattern of weight distribution about their means. There is a right shift
in the off-test weights of vaccinates compared
with controls in each population (Figures 3
and 4). This indicates that within each of these
genetic backgrounds, all the vaccinated pigs
had increased growth rate. Even in apparently
clinically unaffected pigs, the PCV2 virus appears to affect growth rate.
Carcass composition was not affected by
vaccination in this study after adjusting for
off-test weight. Genetic background, however,
did affect carcass traits. Pigs from the Durocbased lines had decreased loin depth and increased backfat compared with pigs from the
Duroc-, Pietrain-, and Large White-based
lines.

The data in this study demonstrate that genetic background affects either the expression
of PCVD or the response to the PCV2 vaccine, as measured by growth performance.
Therefore, genetic background should be considered a risk factor for expression of PCVD
or a factor that affects response to PCV2 vaccine.

There was a clear rise in antibody production by d 40 due to vaccination as indicated by
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Table 1. Effect of PCV2 vaccine treatment and genetic background on ages, weights, growth rates, and carcass characteristics1
Genetic background2
A×B
B×A
Control
Vacc.
Control
Vacc.
60
65
34
32

B×B
Control
Vacc.
55
54

SE4

21.1
151.4
13.5

20.3
150.6
13.8

20.3
150.6
13.9

21.3
151.7
14.5

19.7
150.0
12.8

0.6
0.7
0.7

0.71
0.41
0.51

0.85abc
1.91b
1.59b
220.6b

0.96bd
1.93b
1.63bc
226.7bc

0.90ace
2.02c
1.68bc
232.9bc

0.96bcde
1.02de
1.91bc
2.00bc
b
1.63
1.71c
226.7bc
236.9c

0.05
0.05
0.05
6.5

0.05
0.05
0.04
0.05

A×A
Control3 Vacc.
62
55

Item
no. of pigs
Age, d
Weaning
21.2
Off test
151.5
Weaning weight, lb
12.8
4
ADG , lb
Nursery phase
0.84a
Finisher phase
1.70a
Wean-to-finish
1.44a
Off-test weight, lb
200.9a
Carcass characteristics, mm
Backfat depth
11.4
Loin depth
59.2
Backfat depth
12.2
(weight adjusted)
Loin depth
62.3
(weight adjusted)

21.3
151.7
14.2

19.6
150.0
13.2

0.92abcde
0.88abc
1.88b
1.95bc
bc
1.60
1.60bc
220.7b
225.7bc

Vaccine × Genetic
Probability, P <

12.0
62.2

12.1
65.7

12.0
66.9

11.2
66.3

11.7
69.0

10.6
68.8

10.8
69.6

0.5
1.3

0.46
0.32

12.1

11.9

11.6

11.1

11.2

10.7

10.7

0.5

0.79

62.6

65.1

65.4

65.8

67.1

69.2

69.2

0.9

0.82

Note. Results reported as least squares means.
Within a row, means without a common superscript letter differ (P < 0.05).
1
A total of 454 pigs from 4 genetic backgrounds were assigned to vaccine treatment by ranking them by weight within litter and gender and randomly assigning each pig to either vaccine or nonvaccinate control, balanced by birth weight across vaccine treatment. Pigs were individually
weighed at birth, weaning (d 0), end of nursery (d 40), and off test (d 130). Backfat and loin depth were measured at d 130.
2
Genetic backgrounds used were A×A (Duroc-based sire and dam), A×B, B×A, and B×B (synthetic line for the sire and dam primarily derived from
Duroc, Pietrain, and Large White).
3
Vaccine treatments included vaccinates (2 cc Circumvent PCV, Intervet Inc., Millsboro, Delaware) and nonvaccinated controls. Vaccine was administered intramuscularly at 21 and 35 d of age.
4
SE among treatment groups differed because of unbalanced design. In this table, the highest SE among the treatment groups was reported.
abcde
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Geometric Mean Titer

6000

Control

a
3951

5000
4000
b
1928

3000
2000
1000

Vaccinate

d
234

d
226

c
975

d
189

0
0

40

130

Day on Test
Figure 1. Effect of PCV2 vaccination and time on indirect fluorescent antibody geometric
mean titer (vaccine × time P < 0.01; a,b,c,d P < 0.01).
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Mean template copies/rxn

5000

Control
Vaccinate

a
4582

4000
3000
2000
1000

b
21

0
d 40

Control
Vaccinate

Mean template copies/rxn

50
40
30
20
10

a
3.8

b
1.3

0
d 130

Figure 2. Effect of PCV2 vaccination and time on PCV2 viral template quantity
(a,b P < 0.01 within day).
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Frequency

45%
40%
35%
30%
25%
20%
15%
10%
5%
0%

A×A Control (Avg = 201)
A×A Vaccinate (Avg = 221)

<140 160 180 200 220 240 260 280 300 >300

Weight Category, lb
Figure 3. Distribution of off-test pig weights for control vs. vaccinated pigs of genetic
background A×A.
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Frequency

45%
40%
35%
30%
25%
20%
15%
10%
5%
0%

B×B Control (Avg = 221)
B×B Vaccinate (Avg = 226)

<140 160

180 200 220 240 260

280 300 >300

Weight Category, lb
Figure 4. Distribution of off-test pig weights for control vs. vaccinated pigs of genetic
background B×B.
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